Insulin detemir

Summary

Insulin detemir (Levemir) is a long-acting basal insulin analogue approved for once- or twice-daily subcutaneous injection in adults and children with type 1 or type 2 diabetes mellitus. It provides relatively flat, predictable 24-hour glycemic control with lower risk of nocturnal hypoglycemia and less weight gain compared to NPH insulin.

Mechanism of Action

Insulin detemir is a soluble, long-acting insulin analogue that binds to insulin receptors, activating the receptor tyrosine kinase and downstream signaling pathways (PI3K/Akt, MAPK). It lowers blood glucose by stimulating peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. Its prolonged action results from self-association at the injection site and reversible albumin binding via its C14 fatty acid chain (myristic acid), slowing absorption and distribution.

Routes of Administration

Goals & Uses

• Glycemic control during pregnancy (diabetes)Obstetric/endocrineModerate
• Weight neutrality relative to NPHMetabolicModerate
• Basal glycemic control in type 1 diabetesGlycemic ManagementHigh
• Basal glycemic control in type 2 diabetesGlycemic ManagementHigh
• Reduction of nocturnal hypoglycemiaSafety / TolerabilityHigh

Contraindications

• Intravenous or intramuscular administrationRoute Of AdministrationHigh
• Hypersensitivity to insulin detemir or excipientsImmunologicHigh
• Hypoglycemia (active episode)MetabolicHigh

Adverse Effects

• HypoglycemiaMetabolicCommonAbnormally low blood glucose
• Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
• Injection site reactionsLocalCommon
• Allergic reactions / anaphylaxisImmunologicRare
• Weight gainMetabolicCommonIncrease in body weight
• LipodystrophyDermatologicUncommon

Drug Interactions

• Thiazolidinediones (e.g., pioglitazone)Moderate
• Salicylates (high-dose)Low
• Beta-blockersModerate
• AlcoholModerate
• CorticosteroidsModerate
• Antidiabetic agents (oral hypoglycemics, other insulins)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Elderly patientsAgeRelative
• Pediatric patients (<2 years)AgeRelative

Regulatory Status

• European UnionApprovedApproved: Treatment of diabetes mellitus in adults and children aged 1 year and aboveEMA approved June 2004 (EMEA/H/C/000528). Levemir is the trade name. Periodic safety review ongoing.
• United StatesApprovedApproved: Type 1 diabetes mellitus (adults and pediatric patients ≥2 years), Type 2 diabetes mellitus (adults)FDA approved June 2005 (NDA 021536). Manufactured by Novo Nordisk. Marketed as Levemir.
• United KingdomApprovedApproved: Diabetes mellitus in adults and children from 1 year of ageApproved via EMA prior to Brexit; continued post-Brexit approval by MHRA. Available on NHS prescription.

Approved by the FDA in 2005 and by the EMA in 2004. Pregnancy category B (FDA). Biosimilars may exist in some jurisdictions. Levemir FlexPen is available as a prefilled delivery device.

Evidence & Sources

No sources recorded yet.